Novo Nordisk A S annual free cash flow per share
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Free Cash Flow Per Share Growth & History (NVO)
Novo Nordisk A S's free cash flow per share was DKK 13.27 for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | DKK 13.27 | -DKK 3.30 | −19.91% |
| 2024 | 2024-12-31 | DKK 16.57 | -DKK 1.97 | −10.61% |
| 2023 | 2023-12-31 | DKK 18.54 | DKK 3.81 | +25.84% |
| 2022 | 2022-12-31 | DKK 14.73 | DKK 4.14 | +39.04% |
| 2021 | 2021-12-31 | DKK 10.60 | DKK 0.71 | +7.22% |
| 2020 | 2020-12-31 | DKK 9.88 | DKK 1.91 | +23.97% |
| 2019 | 2019-12-31 | DKK 7.97 | — | — |
Novo Nordisk A S quarterly free cash flow per share
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | DKK 9.60 | DKK 3.51 | +57.50% |
| Q1 2026 | 2026-03-31 | DKK 2.71 | — | — |
| Q4 2025 | 2025-12-31 | -DKK 2.43 | — | — |
| Q3 2025 | 2025-09-30 | DKK 7.06 | — | — |
| Q2 2025 | 2025-06-30 | DKK 6.10 | — | — |
Novo Nordisk A S free cash flow per share trends
Over the last five fiscal years, Novo Nordisk A S's free cash flow per share increased from DKK 9.88 to DKK 13.27, a change of DKK 3.39. The latest reported quarter, Q2 2026, shows DKK 9.60.
About the metric
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
Calculation and source
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...